Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.62 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.62 |
| ▸ | SIK1 | P57059 | 1/20 | 0.62 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
| ▸ | INSR | P06213 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317802 | 0.92 | SIK2 (0.73) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25882140 | 0.92 | CSF1R (0.62) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25881963 | 0.91 | CSF1R (0.60) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25314439 | 0.91 | CSF1R (0.57) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25311523 | 0.90 | SIK2 (0.70) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25314224 | 0.87 | CSF1R (0.54) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL25882412 | 0.87 | SIK2 (0.69) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL30309525 | 0.86 | SIK2 (0.64) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL22086961 | 0.84 | SIK2 (0.85) | CSF1RSIK2SIK1SIK3EGFR | |
| SCHEMBL30309616 | 0.83 | CSF1R (0.60) | CSF1RSIK2SIK1SIK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | CSF1R 28/4885SIK2 116/4885SIK1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.